
Internal Reference Number: FOI_8820
Date Request Received: 05/08/2025 00:00:00
Date Request Replied To: 19/08/2025 00:00:00
This response was sent via: By Email
Request Summary: Atopic Dermatitis
Request Category: Researcher
| Question Number 1: I am analysing the treatment of dermatological conditions in the UK. Could you please answer the following questions. How many patients were treated in the last 4 months (April to July 2025) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Lebrikizumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) - for Atopic Dermatitis only • Tacrolimus ointment • Tralokinumab • Upadacitinib • Nemolizumab | |
| Answer To Question 1: Please see our response in the attached file. To accompany this answer to question 1 please also see the documents listed below: | |
| Question Number 2: In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department • Abrocitinib • Baricitinib • Dupilumab • Lebrikizumab • Tralokinumab • Upadacitinib • Nemolizumab *Patients are considered initiated on a treatment if they have not been treated with the named treatment in the previous 8 months. | |
| Answer To Question 2: Please see our response in the attached file. | |
| Question Number 3: Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • 6 months to 5 • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 3: Please see our response in the attached file. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.